Clinical Trial Detail

NCT ID NCT03735875
Title Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Quizartinib + Venetoclax

Age Groups: adult senior

Additional content available in CKB BOOST